Natco Pharma board meets Aug 14 to consider raising funds

Natco Pharma will hold a meeting of its Board of Directors on August 14, 2026, to consider and evaluate proposals for raising funds through the issuance of equity shares or other securities. The potential fundraising methods include public issues, preferential issues, rights issues, private placements, qualified institutions placements, or any combination thereof, subject to market conditions and necessary regulatory approvals.

The intimation was issued pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This notice serves as an update to an earlier intimation dated August 6, 2026, regarding the scheduling of the board meeting.

Fundraising Options Under Consideration

The Board is evaluating multiple avenues for capital raising. The specific instruments under consideration are detailed below:

Instrument Type	Description
Public Issue	Offering shares to the general public
Preferential Issue	Allotment of shares to specific investors
Rights Issue	Offering shares to existing shareholders
Private Placement	Issuance to selected institutional or high-net-worth investors
Qualified Institutions Placement (QIP)	Issuance to qualified institutional buyers

Any decision to proceed with these measures will be subject to prevailing market conditions and the receipt of all required regulatory, statutory, and other approvals as mandated by applicable laws.

Compliance and Disclosure

Ch. Venkat Ramesh, Company Secretary & Compliance Officer of Natco Pharma Limited, signed the intimation letter dated August 11, 2026. The company has submitted this disclosure to both the BSE Limited and the National Stock Exchange of India Limited for record-keeping purposes, in compliance with listing obligations.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.38%	-2.38%	-7.83%	+7.09%	+0.80%	-7.73%

Natco Pharma has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for Olaparib tablets (100 mg and 150 mg). The product is bioequivalent to the reference listed drug Lynparza® tablets of AstraZeneca Pharmaceuticals for the indication in the approved labelling. Alembic Pharmaceuticals will distribute the product in the U.S. market.

U.S. Market Opportunity

The estimated sales for Olaparib tablets were approximately USD 1.4 billion in the U.S. for the 12 months ending March 2026, according to industry sales data. The Para IV litigation regarding the product is currently ongoing.

Product and Regulatory Details

The key details surrounding this development are outlined below:

Parameter:	Details
Regulatory Approval:	Tentative U.S. FDA Approval
Product:	Olaparib Tablets (100 mg, 150 mg)
Reference Listed Drug:	Lynparza® tablets (AstraZeneca Pharmaceuticals)
U.S. Distribution Partner:	Alembic Pharmaceuticals
Estimated U.S. Sales (12 months ending Mar'26):	~USD 1.4 billion